Pfizer leaves investors guessing on intentions for AstraZeneca

July 30th, 2014 Pfizer Inc, which in May abandoned its $118 billion bid for AstraZeneca Plc, on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals. The largest U.S. drugmaker reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines. But overall sales fell on competition …

Pfizer Announces Submission of Biologics License Application to the FDA for Investigational Meningococcal B Vaccine

June 17, 2014 Pfizer Inc. announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. Each year, approximately 500,000 cases of meningococcal disease occur worldwide …

American College of Physicians, CECity, and Pfizer collaborate to increase adult immunization rates

Public health initiative aims to increase unacceptably low adult vaccination rates May 14, 2014 The American College of Physicians (ACP), CECity, and Pfizer Inc. today announced a new initiative designed to increase adult immunization rates by assisting physicians and other health care providers in strongly recommending appropriate vaccination and tracking adult immunization rates for quality measurement and improvement. The three …

Pfizer Announces Positive Phase 2 Study Results for Investigational Meningococcal B Vaccine

May 9, 2014 Pfizer Inc. announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer’s recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. In both studies, bivalent rLP2086 was observed to generate bactericidal responses, a measurement of functional immune response, against diverse …

Pfizer Presents Results From Landmark Community-Acquired Pneumonia Immunization Trial In Adults Evaluating Efficacy Of Prevenar 13*

Study Findings, Presented at ISPPD, Demonstrate that Prevenar 13 Can Prevent Vaccine-Type Community-Acquired Pneumonia March 12, 2014 Pfizer Inc. today presented detailed results of the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the landmark study of approximately 85,000 subjects, demonstrating that Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) prevented a first episode of vaccine-type community-acquired pneumonia (CAP) in adults 65 …

Pfizer Reaches Primary and Secondary Objectives in Landmark Community-Acquired Pneumonia Vaccination Trial

February 24, 2014 Pfizer Inc. today announced that the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the landmark study of approximately 85,000 subjects evaluating the efficacy of Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 65 years of age and older, achieved its primary clinical objective and both secondary clinical objectives.  CAPiTA is the largest double-blind, randomized, placebo-controlled …